Karyopharm Therapeutics (KPTI) PT Raised to $22 at Baird; 'Expect a transformational year'
Tweet Send to a Friend
Baird raised its price target on Karyopharm Therapeutics (NASDAQ: KPTI) to $22.00 (from $15.00) while maintaining a Outperform rating.Analyst Michael ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
